This has been a really exciting year for ASCO. It’s not common that sarcoma makes it into the literature, so we were really excited to have the results of SARC-041 be presented by Dr. Mark Dickson from Memorial Sloan Kettering. This really establishes a new potential standard of care for dedifferentiated liposarcoma with the demonstration of abemaciclib and gemcitabine over placebo for these patients...
This has been a really exciting year for ASCO. It’s not common that sarcoma makes it into the literature, so we were really excited to have the results of SARC-041 be presented by Dr. Mark Dickson from Memorial Sloan Kettering. This really establishes a new potential standard of care for dedifferentiated liposarcoma with the demonstration of abemaciclib and gemcitabine over placebo for these patients. We know for these patients that doxorubicin has marginal benefit for many patients, and I think abemaciclib really provides a promising new option for these patients. Otherwise, in the oral abstract sessions, very notable trials, I think, that were highlighted were the PEAK study for bezuclastinib and sunitinib compared to sunitinib alone, which has a very promising potential to transform care as well. And of course, the immunotherapy study with varegacestat also provides new armamentarium for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
